79 results about "Colon specific" patented technology

The present invention relates to an oral pharmaceutical preparation having an excellent capability of delivering a drug to colon, more specifically an oral pharmaceutical preparation for delivering a drug to colon and comprising a core comprising at least a pharmaceutically acceptable vehicle, an inner layer covering said core and comprising said drug, an intermediate layer covering said inner layer and comprising a cationic polymer soluble or swellable at a pH of not more than 6.6, and an outer layer covering said intermediate layer and comprising an anionic polymer soluble at a pH of not less than 7.0.

Drug delivery systems that can deliver therapeutic and/or diagnostic agents to the colon are disclosed. The systems include pectin beads crosslinked with zinc or any divalent cation of interest, which beads are then coated with Eudragit®-type polymers. The drug delivery systems are orally administrable, but can deliver the active agents to the colon. In some embodiments, they can administer the agents to various positions in the gastro-intestinal tract, including the colon. The agent can be a small molecule, peptide, protein, nucleic acid, or complex structures of natural, recombinant or synthetic origin. In still other embodiments, the agent is a diagnostic agent. The agents can be used to diagnose, treat or investigate humans and animals for a variety of conditions, including infectious diseases, inflammatory diseases, cancers and the like. Colon-specific delivery is obtained by formulating a prophylactic, therapeutic, and/or diagnostic agent with specific polymers that degrade in the colon, such as pectin. The pectin is gelled/crosslinked with a cation such as a zinc cation. The formulation, typically in the form of ionically crosslinked pectin beads, is subsequently coated with a specific polymer such as a Eudragit® polymer. Processes for obtaining such beads are also disclosed.

The invention discloses an oral mesalazine colon-specific adhesive preparation with a high drug-loading rate, which can be used for effectively treating ulcerative colitis and segmental ileitis, as well as a preparation method of the oral mesalazine colon-specific adhesive preparation. The preparation is composed of a pill-containing core and an enteric coating layer, wherein the pill-containing core consists of mesalazine, excipient, adhesive and boning agent. Compared with the other oral preparations, the oral mesalazine colon-specific adhesive pellet has the effects of improving the curative effect and lowering adverse reactions when the dosage is the same. Compared with enema and suppository, the pellet has better tolerance. The preparation method can be used for effectively controlling the temperature in the production process and avoiding an overheating phenomenon in the preparation process, and is simple in preparation process and high in drug-loading rate. Besides, the oral mesalazine colon-specific adhesive pellet is applicable to the large-dose dosing characteristic of mesalazine, thereby reducing the medicine taking inconvenience of a patient and improving the dependence of the patient.

The invention relates to an oral colon targeted drug delivery composition capable of reducing toxic and side effects of rheum officinale anthraquinone and application of the oral colon targeted drug delivery composition. The oral colon targeted drug delivery composition is composed of rheum officinale anthraquinone subjected to freeze drying and auxiliary materials, wherein the auxiliary materials are selected from a colon specificity enzymatic degradable material, a material soluble in medium with pH more than or equal to 6.8, a filler and a bonding agent. The oral colon targeted drug delivery composition can not weaken purgation effect of rheum officinale and also can be used for effectively preventing toxicity of rheum officinale from being played after colon-targeted drug delivery and is basically non-toxic after being taken for a long time, so that the problem of pharmaceutical toxicity of rheum officinale is solved.

The invention discloses a colon specific targeting drug-delivery preparation of cerebroprotein polypeptides and its preparing process, wherein the preparation is prepared through coating the drug-containing micro-pellets made from medicinal powder containing cerebroprotein polypeptides components with colon targeting coating layer, or directly loading the drug-containing micro-pellets into the shells of the colon targeting capsule. The process for preparing the colon targeting drug-delivery preparation of the cerebroprotein polypeptides consists of producing drug-containing micro-pellets containing cerebroprotein polypeptides components, then preparing the colon targeting coating liquid, finally coating the drug-containing micro-pellets with the colon targeting coating liquid. The preparation provided by the invention can make the colon release drugs enter blood circulation through colon, thereby avoiding metabolism destruction of the conventional oral preparation peptides drugs on the stomach, as a result, the therapeutic action of the drugs can be sufficiently exploited.

The invention belongs to the technical field of the biological medicine, and particularly relates to a cation-modified konjac glucomannan gellan gum microsphere as well as a preparation method and an application. The cation-modified konjac glucomannan gellan gum microsphere is prepared from a nucleic acid drug and a drug delivery carrier, wherein the nucleic acid drug is ribonucleic acid or desoxyribonucleic acid, and a drug delivery system comprises the components as follows: 20-30 parts of cKGM (cation konjac glucomannan), 1-9 parts of gellan gum and 0.01-6 parts of the nucleic acid drug. According to the microsphere, the requirement for colon-specific drug delivery of the oral microsphere is met, and the microsphere is simple in preparation technology and easy to industrialize and has very broad development and application prospects.

The invention relates to a novel colon-specific drug delivery system (CSDDS) and preparation method. The capsule CSDDS has the advantages that the release control principle is clear, the preparation process is simple, the drug release is precise, the scope of suitable drugs is wide, and the drug release adjustment is convenient. The capsule CSDDS provided by the invention comprises an insoluble capsule, an enzymolysis capsule, a soluble capsule cap and an enteric coating, can be used for filling chemical medicaments, traditional Chinese medicines, biological product medicines, and the like, and can be used for controlling the release of the medicaments on a colon part. The insoluble capsule of the CSDDS can be prepared by using a conventional capsule shell preparation method; the enzymolysis capsule can be prepared by using a conventional tabletting method; the enteric coating can be prepared by using a fluidized bed method; and a release test shows that the capsule shell has the advantage of controlling the medicaments to release at the colon part.

The invention discloses a colonic targeting drug-delivery soft capsule, which comprises a brucea javanica oil soft capsule and high polymer coating film, wherein the high polymer coating film is pH-sensitive enteric coated cover which contains component of ethyl cellulose or acetyl cellulose. The invention provides accurate composition of high polymer coating film, realizes indisintegration of soft capsule after being coated in the buffer solution with pH value less than seven and disintegration in the buffer solution with pH value more than seven, and achieves requirements of ideal colon-specific drug delivery. The invention with simple process for preparation and mature process condition compensates the blank that no soft capsule for colon drug delivering is developed and applied.

This invention relates to a pH dependent compound bone peptide preparation and its preparation method and application. The preparation method comprises carrying out pretreatment of animal bones of limbs powder and cucumber seed powder, extracting compound bone peptide, concentrating, clathrating with beta-cyclodextrin, and making into colon-specific slow release capsule or tablet in order to avoid gastric juice hydrolysis and hepatic first pass effect to destroy its bioactivity. The compound bone peptide has a molecular weight below 5000 Daitor, and can be used for preventing fracture and osteoporosis, treating ostalgia, rheumatism and rheumatoid diseases.

The invention discloses a method for preparing a colon-specific pressed coated tablet. The method comprises the following steps: (1) mixing Konjac Glucomannan, xanthan gum or carrageenan and a diluting agent; adding an adhesive to the mixture, pelletizing the mixture by a wet method, drying the mixture until constant weight, finishing pellets, and adding a lubricating agent to the mixture to evenly mix, so as to obtain a coating material of the colon-specific pressed coated tablet; (2) evenly mixing bulk drugs and a disintegrant, adding an adhesive to the mixture, pelletizing the mixture by the wet method, drying the mixture until constant weight, finishing pellets, and adding the lubricating agent to the mixture to evenly mix, so as to obtain a drug-contained tablet core; and (3) coating the coating material of the colon-specific pressed coated tablet outside the drug-contained tablet core to be prepared into the colon-specific pressed coated tablet. The colon-specific pressed coated tablet prepared by the method has the characteristic of obvious colon-specific release effect, can conveniently regulate the release process of the tablet through changing the thickness of a coating outer layer, the proportion of blending amylose and the content of the diluting agent. The method has the advantages of wide drug loading system, wide raw material source, low price and simple preparation process.

The invention discloses a production of a mesalazine colon-specific drug administration sustained-release tablet. The mesalazine (5-ASA) is widely applied clinically, and becomes a priority drug for treating inflammatory bowel diseases. The mesalazine is ineffective when being orally taken, because the mesalazine is quickly absorbed in the small intestine, then acetylated and discharged along with urine, thus being not able to reach the colon part. 5-ASA can only play the treatment function when reaches the colon lesion part in a prototype, and is produced into a pH-dependent colon-specific drug administration sustained-release tablet, so that the 5-ASA drug which reaches the colon has enough concentration to have an anti-inflammatory effect. Eudragit L100 and Eudragit S100 can be used to produce a film coating which meets the colon-specific release requirement according to a certain proportion. The mesalazine is produced into a coating sustained-release tablet, so that the 5-ASA drug which reaches the colon has enough concentration to achieve the anti-inflammatory effect.

The invention relates to an oral colon-specific release film coating premixed accessory of a pH dependent type, characterized by mainly comprising the following components in percentage by weight: 40-70 percent of polyacrylic acid resin III, 15-23 percent of plasticizer and the balance of accessory materials, wherein the polyacrylic acid resin III has the viscosity number of 20-35 mPa*s and the acid number of 210-220. The technical scheme of the invention has the effects of low cost, favorable disintegration release performance and less and non-sensitive coating weight increase.

The invention pertains to the field of pharmaceutical preparation. The invention relates to a cross-linked covered tablet which is used for colon-specific drug delivery. The invention takes a drug-containing tablet as the core, the periphery of which is wrapped with a coating material, and the outer layer coating retarding material adopts the mixture of pectin of the calcium salts/calcium salts with the special amount and high parts by weight; the retarding release effect of the pectin is strengthened through the cross-linked process, so the invention is applicable to the colon-specific drug delivery, in particular to the insoluble drugs. The experimental results show that the invention can retard the release of the drug, so as to achieve the ideal colon-specific drug delivery, at the same time, the invention does not need to use more coating materials, which can significantly save the using amount of the pectin materials. The invention is applicable to the treatments of the diseases with the need of colon-specific drug delivery, such as colitis, colon cancer and other colon diseases.

The invention discloses a preparation method of microencapsulated capsicin. The preparation method includes the steps: (1) melting capsicin in water bath by heating, and adding an emulsifier to prepare a core emulsion; (2) adding chitosan, pectin and calcium chloride into water to prepare a wall material solution; (3) adding the core emulsion into the wall material solution, mixing, adding a curing agent prior to mixing, and spraying and drying to obtain the microencapsulated capsicin. The microencapsulated capsicin has the advantages that stimulation of the capsicin on digestive tract mucosae is reduced, application range of the capsicin is enlarged, and the capsicin can not only be used in condiments but also applied to health care products; the microencapsulated capsicin is good in solubility and high in stability; a barrier function of drug delivery on upper segments of the gastrointestinal tracts can be enhanced, and colon-specific drug delivery of preparations is facilitated; the method is simple to operate and easy for industrial production, and a feasible technical route is provided for development of the capsicin.

The invention discloses a colon-specific pH sensitive hydrogel, a preparation method and an application thereof. The hydrogel is prepared by mixing glycerol monostearate serving as a delayed-release material and medicines, uniformly coating the surface of the mixture with sodium alginate with a certain concentration, and baking. The in vitro drug release behavior is taken as an index to investigate the concentrations of sodium alginate and calcium chloride, the calcification time and the drug-release behavior of drug loading capacity on medicines in artificial gastric juice for 2 hours, artificial intestinal juice for 4 hours and artificial colonic juice for 4 hours, and the optimal hydrogel for the in vitro drug release behavior is screened. According to the colon-specific pH sensitive hydrogel, release of a medicine in a pH 6.8 environment can be effectively controlled by using the glycerol monostearate as a delayed-release material, and the targeting property can be further improved after the natural polysaccharide material sodium monostearate is coated, so that the glycerol monostearate is not released or little released in pH1.2, and over 90 percent of the medicine can reach the colon part.

The invention discloses a folate-receptor-mediated curcumin self-microemulsion colon-specific delivery preparation, which is composed of the following components in parts by weight: 0.05-7.5 parts of curcumin, 10-40 parts of oil phase, 30-60 parts of surfactant, 30-60 parts of cosurfactant and a folic acid lipid material the amount of which accounts for 0.01-3% the weight of the surfactant. In the invention, curcumin is processed into a self-microemulsion preparation, which is composed of a pharmaceutically common oil phase, a surfactant and a cosurfactant, and the solubility of curcumin can be increased by the oil phase, surfactant and cosurfactant; when the oil phase, surfactant and cosurfactant are mixed in an appropriate ratio, an O/W microemulsion can be formed in water by self-microemulsification, so that the solubility of curcumin is up to 30-70 mg/mL and the solubility is increased by more than 40000 times; and the solubility of turmeric is effectively improved, the oral absorption availability of the preparation is improved, and the preparation has the advantages of strong targeting, simple preparation method, low cost, etc.

The invention provides a colon-specific bioadhesive tablet containing monosialotetrahexosyl ganglioside sodium. The colon-specific bioadhesive tablet comprises a tablet-loaded core and a coating wrapping the tablet-loaded core, wherein the tablet-loaded core is prepared from monosialotetrahexosyl ganglioside sodium and a pharmaceutical carrier, and the coating is mainly prepared from ethyl cellulose, zein, dibutyl phthalate, stevioside and mannitol. The colon-specific bioadhesive tablet containing monosialotetrahexosyl ganglioside sodium has the high colon-specific drug release degree; due to the fact that when the bioadhesive tablet is in the stomach and the small intestines, the release degree of the active ingredients of the drug is low, the risk that the active ingredients of the drug are degraded in the stomach is reduced, and the stability of the drug in the stomach and the small intestines is improved; when the bioadhesive tablet reaches the colon, the bioadhesive tablet starts releasing the active ingredients of the drug, and therefore the pharmaceutical effect of the bioadhesive tablet is improved.

The polymers, according to the invention, comprise a polysaccharide block (17) and several hydrophobic polyacrylic blocks (18) enabling the polymer to remain intact until the polymer reaches the colon. The polysaccharide block is degraded by the colonic microflora irrespective of the pH, while the polyacrylic blocks are solublilized at neutral pH. Colon-specific release of the active ingredients is thus provided in all cases. These polymers may serve as a coating in particular for tablets, gel capsules, granules or microgranules, or serve as matrix agents in the preparation of such pharmaceutical forms. This invention concerns the fields of medicine, pharmacy and dietetics.